Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Fabry disease Stories

2013-10-03 09:29:44

A genetic condition that attacks multiple organs and usually results in fatal heart problems can be detected using a new MRI technique that was developed at the University of Alberta. The discovery of this new diagnostic tool has resulted in updated clinical guidelines for the diagnosis and treatment of Fabry disease in Canada. Faculty of Medicine & Dentistry researchers Gavin Oudit and Richard Thompson worked with Faculty colleagues Kelvin Chow and Alicia Chan on the discovery, as...

2013-07-19 12:24:35

CANTERBURY, England, July 19, 2013 /PRNewswire/ -- Dr Mark J Hudson-Peacock is excited to be the first doctor in the UK to be offering this revolutionary treatment to sufferers with haemorrhoid disease (HD or piles), which is so common, but not much spoken about. Many sufferers with HD do not seek help, as they are too embarrassed or scared that treatment might mean pain or disruption to their everyday lives. HD can affect people from all walks of life, and it is stated...

2013-02-28 04:21:45

LEXINGTON, Massachusetts, February 28, 2013 /PRNewswire/ -- - Global Initiatives Underscore Company's Long-Term Commitment to the Rare Disease Community Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease Day, joining patients, healthcare providers, and patient organizations around the world to support a day that focuses attention on rare diseases as a public health issue, and highlights the need for more understanding and awareness about these...

2012-03-29 06:26:00

NYON, Switzerland, March 29, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented data that show favorable treatment effect and tolerability of REPLAGAL® (agalsidase alfa) in Fabry patients who switched from Fabrazyme® (agalsidase beta) or were naive to enzyme replacement therapy (ERT) after one year of treatment with REPLAGAL at the America College of Medical Genetics (ACMG) annual meeting in Charlotte, NC....

2012-03-14 14:30:00

LEXINGTON, Massachusetts, March 14, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has withdrawn its Biologics License Application (BLA) for REPLAGAL(R) (agalsidase alfa) with the US Food and Drug Administration (FDA). Shire has been in ongoing dialogue with the FDA since the supply shortage of the only US approved treatment for Fabry disease. In 2009, and again in 2011, the FDA encouraged...

2012-02-09 06:00:00

DUBLIN, Ireland, February 9, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the year to December 31, 2011. Financial Highlights Full Year 2011(1) Product sales $3,950 million +26%...

2011-12-22 15:36:45

A research team led by biochemist Scott Garman at the University of Massachusetts Amherst has discovered a key interaction at the heart of a promising new treatment for a rare childhood metabolic disorder known as Fabry disease. The discovery will help understanding of other protein-folding disorders such as Alzheimer's, Parkinson's and Huntington's diseases, as well. Findings are featured as the cover story in the current issue of Chemistry & Biology. People born with Fabry disease...

2011-10-26 06:30:00

CARMIEL, Israel, Oct. 26, 2011 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), today announced that senior management will present at four upcoming conferences: Ernst & Young Journey 2011 Conference Wednesday, November 2, 2011 at 2:45 PM IDTTopic: The Pfizer-Protalix Gaucher Collaboration - The Partners' Point of ViewDr. David Aviezer, President & CEOHilton Hotel, Tel-Aviv, Israel PDA-Parenteral Drug Association / FDA-Food and Drug Administration:...

2011-08-31 09:09:00

NYON, Switzerland, Aug. 31, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase). Study results are being presented at the 2011...

2011-07-20 14:42:58

Research highlights importance of rare disease registers Spanish patients with Fabry disease, a rare hereditary condition where abnormal fatty deposits collect in blood vessels and organs throughout the body, appear to react differently to those in other European countries, according to a study in the August issue of IJCP, the International Journal of Clinical Practice. Researchers from three university hospitals say that the Spanish patients showed a different pattern of organ involvement in...